Antitumor active furan-substituted hexafluoroisopropyl sulfide, its preparation method and application

The preparation method of furan-substituted hexafluoroisopropyl sulfide compounds solves the problems of limited source of hexafluoroisopropyl sulfide compounds and harsh reaction conditions in the prior art, and realizes the synthesis of highly efficient and low-cost antitumor active compounds.

CN123106592APending Publication Date: 2026-11-17RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611163636.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-03
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing synthetic processes have limited sources of hexafluoroisopropylthio compounds, demanding reaction conditions, and numerous side reactions, resulting in a lack of hexafluoroisopropylthio compounds with antitumor activity.

Method used

The preparation method of furan-substituted hexafluoroisopropyl sulfide compounds involves dissolving an enynyl ketone substrate, hexafluoroacetone, triphenylphosphine, and a catalyst in a reaction solvent at room temperature and stirring. Then, thionyl chloride is added and the mixture is heated and stirred to obtain the target product, hexafluoroisopropyl sulfide.

Benefits of technology

A simple and efficient synthesis of furan-substituted hexafluoroisopropyl sulfide was achieved, which exhibits strong antitumor activity, mild operating conditions, low cost, simplified operation steps, and high yield of the compound.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106592A_ABST
    Figure CN123106592A_ABST
Patent Text Reader

Abstract

This invention discloses an antitumor active furan-substituted hexafluoroisopropyl sulfide, the structure of which is shown in the following formula: In formula I, R1 is one of carbonyl, alkoxyacyl, and benzyloxyacyl; R2 is one or more of alkyl, aryl, heteroaryl, halogen, and methyl; and R3 is one of hydrogen, alkyl, and halogen. The furan-substituted hexafluoroisopropyl sulfide of this invention exhibits strong antitumor activity; moreover, the preparation method involved is simple and rapid, operates under mild conditions, has low cost, and high yield, making it suitable for widespread application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of organic chemistry technology, specifically relating to an antitumor active furan-substituted hexafluoroisopropyl sulfide, its preparation method, and its application. Background Technology

[0002] Fluorine-containing compounds, due to their unique physical, chemical, and biological properties, have found wide application in many fields such as biomaterials, medicine, pesticides, and the aerospace industry. Statistics show that as many as 15-20% of drugs launched to the market each year contain fluorine atoms, fully demonstrating the indispensable role of fluorine atoms and fluorine-containing groups in drug innovation.

[0003] However, despite the significant achievements of fluorine chemistry in medicinal chemistry, reports on the synthesis of molecules containing hexafluoroisopropylthio groups are relatively few. Furthermore, existing synthetic processes suffer from limitations such as limited sources of hexafluoroisopropylthio groups, harsh reaction conditions, and numerous side reactions. Further exploration of α-hexafluoroisopropylthio compounds with antitumor activity that can be prepared under mild conditions has significant research and application implications. Summary of the Invention

[0004] The main objective of this invention is to provide a series of furan-substituted hexafluoroisopropyl sulfide compounds.

[0005] Another objective of this invention is to provide a simple and efficient method for preparing furan-substituted hexafluoroisopropyl sulfide, and its application as an antitumor active molecule.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows: An antitumor active furan-substituted hexafluoroisopropyl sulfide, the structure of which is shown in Formula I:

[0007] I In Formula I, R1 is one of carbonyl, alkoxyacyl, benzyloxyacyl, etc.; R2 is one or more of alkyl, aryl, heteroaryl, halogen, and methyl; and R3 is one of hydrogen, alkyl, and halogen.

[0008] Further, in R2, the alkyl group is a C1-C4 straight-chain alkyl group; the heteroaryl group is thiophene; in R3, the alkyl group is a C1-C5 straight-chain alkyl group; further, the specific structural formula of the antitumor active furan-substituted hexafluoroisopropyl sulfide includes the following: or .

[0009] The preparation method of the above-mentioned antitumor active molecule furan-substituted hexafluoroisopropyl sulfide includes the following steps: 1) Under a protective atmosphere, the enynyl ketone substrate, hexafluoroacetone, triphenylphosphine (PPh3) and catalyst were dissolved in the reaction solvent and stirred at room temperature. 2) Inject thionyl chloride (SOCl2) into the reactants obtained in step 1), and then heat and stir the reaction to obtain the target product hexafluoroisopropyl sulfide.

[0010] In the above scheme, the protective atmosphere can be argon or the like.

[0011] In the above scheme, the enynone can be selected from one or more of the following: conjugated enynone, ketone carbonyl-terminated conjugated enynone, alkynyl-terminated conjugated enynone, etc.

[0012] Furthermore, the structural formula of the conjugated enynone ketone with the carbonyl end substituted is shown in Formula II;

[0013] II Furthermore, the structural formula of the conjugated enynone with alkynyl-terminus substitution is shown in Formula III;

[0014] III In the above scheme, the catalyst is one or more of palladium catalysts, copper salt catalysts, iron catalysts, nickel catalysts, etc.

[0015] Furthermore, the palladium catalyst can be selected from one or more of PdCl2, Pd2(dba)3, Pd(PPh3)2Cl2, etc.; the copper salt catalyst can be selected from one or more of Cu(OAc)2, CuBr2, etc.; the iron catalyst can be selected from one or more of Fe(OAc)2, Fe(OAc)3, etc.; and the nickel catalyst can be selected from one or more of NiCl2, NiBr2, NiBr2·glyme, etc.

[0016] In the above scheme, the reaction solvent can be one or more of the following solvents: toluene, carbon tetrachloride (CCl4), 1,2-dichloroethane (DCE), 1,1,2-trichloroethane (CHCl2CH2Cl), and 1,1,2,2-tetrachloroethane (CHCl2CHCl2).

[0017] In the above scheme, in step 1), the obtained reaction mixture is sealed (by means of covering with a stopcock or other means) and then stirred at room temperature.

[0018] In the above scheme, the room temperature stirring reaction time is 1~20 min; the preferred time is 8~12 min.

[0019] In the above scheme, the molar ratio of conjugated enyne ketone, hexafluoroacetone hydrate, triphenylphosphine, thionyl chloride, and catalyst is 1:1.3-1.5:3.5-3.8:1.8-2.2:0.1-0.15.

[0020] In the above scheme, the heating and stirring reaction is carried out under sealed conditions (such as by covering with a stopcock); the temperature used is 105-115°C. o C, the time is 10-12 hours.

[0021] This invention also provides an application of the above-mentioned antitumor active furan-substituted hexafluoroisopropyl sulfide as an antitumor active agent. Compared with the prior art, the beneficial effects of this invention include: (1) The furan-substituted hexafluoroisopropyl sulfide of the present invention has strong antitumor activity; (2) The preparation method used in this invention is simple and rapid, with mild conditions and low cost, and has a wide range of applications; (3) The present invention can effectively simplify the operation steps and ensure the efficient synthesis of high-yield compounds. Attached Figure Description

[0022] Figure 1 The structural formulas of the enynyl ketone substrate raw materials used in Examples 1-14 are shown below; Figure 2 The structural formulas of the enynyl ketone substrate raw materials used in Examples 15-27 are shown below; Figure 3 The structural formulas of the enynyl ketone substrate raw materials used in Examples 28-34 are shown. Detailed Implementation

[0023] To clearly illustrate the purpose, technical solution, and implementation effects of this invention, a detailed description is provided below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative of the technical principles, process steps, and application effects of this invention and do not constitute a limitation on the scope of protection of this invention. Any reasonable adjustments and changes made to process parameters, raw material ratios, or operating conditions based on the technical concept of this invention should be considered to fall within the scope of protection of this invention.

[0024] Example 1 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically methyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester (compound 1), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, methyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate (CAS code 1927889-98-2; methyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate; structural formula see Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h. 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 207 mg of methyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 1, with a yield >99%.

[0025] 1 H NMR (400 MHz, CDCl3) δ 7.50 – 7.45 (m, 2H), 7.40 (q, J = 7.7, 7.0Hz, 3H), 6.58 (s, 1H), 5.30 (s, 1H), 3.81 (s, 3H), 3.46 (sept, J = 7.7 Hz,1H), 2.57 (s, 3H). 13 C NMR (151 MHz, CDCl3) δ 164.1, 160.5, 148.9, 135.6, 129.3, 129.2,128.7, 123.1 (q, J = 279.8 Hz), 114.3, 110.7, 51.6, 50.7 (sept, J = 31.2 Hz),48.4, 13.9. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.7 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C17H15F6O3S+ 413.0641, found413.0628.

[0026] Compound 1 Example 2 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester (compound 2), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate (CAS code 1927890-00-3; structural formula see [link to structural formula]) was prepared. Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol), CF3COCF3·3H2O (0.7 mmol), Pd(PPh3)2Cl2 (0.07 mmol), and PPh3 (1.8 mmol). 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw up SOCl2 (1.0 mmol) and inject it into the solvent. Then close the stopcock and stir at 110°C for 12 h.

[0027] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 215 mg of ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 2, with a yield >99%.

[0028] 1 H NMR (400 MHz, CDCl3) δ 7.52 – 7.45 (m, 2H), 7.45 – 7.34 (m, 3H), 6.59 (s, 1H), 5.30 (s, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.46 (sept, J = 7.7 Hz,1H), 2.57 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.7, 160.3, 148.7, 135.6, 129.3, 129.2,128.8, 123.1 (q, J = 280.0 Hz), 114.6, 110.7, 60.5, 50.7 (sept, J = 31.2 Hz),48.4, 14.5, 14.0. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.7 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C18H17F6O3S+ 427.0797, found427.0813.

[0029] Compound 2 Example 3 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically isopropyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester (compound 3), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, isopropyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate (CAS code 3055811-02-1; structural formula see [link to structural formula]) was prepared. Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0030] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 176 mg of isopropyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 3, with a yield of 80%.

[0031] 1 H NMR (400 MHz, CDCl3) δ 7.53 – 7.46 (m, 2H), 7.45 – 7.35 (m, 3H), 6.58 (s, 1H), 5.30 (s, 1H), 5.15 (sept, J = 6.3 Hz, 1H), 3.46 (sept, J = 7.7Hz, 1H), 2.56 (s, 3H), 1.31 (dd, J = 6.2, 1.2 Hz, 6H). 13 C NMR (151 MHz, CDCl3) δ 163.2, 160.1, 148.6, 135.7, 129.3, 129.2,128.7, 123.1 (q, J = 279.6 Hz), 115.0, 110.8, 68.0, 50.7 (sept, J = 31.2 Hz),48.4, 22.1, 14.0. 19 F NMR (376 MHz, CDCl3) δ -69.5 – -69.6 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C19H19F6O3S+ 441.0954, found441.0970.

[0032] Compound 3 Example 4 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically butyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester (compound 4), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, butyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate (CAS code 2258609-49-1; structural formula see [link to structural formula]) was prepared. Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol), CF3COCF3·3H2O (0.7 mmol), Pd(PPh3)2Cl2 (0.07 mmol), and PPh3 (1.8 mmol). 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h. 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 230 mg of butyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 4, with a yield >99%.

[0033] 1 H NMR (400 MHz, CDCl3) δ 7.51 – 7.46 (m, 2H), 7.44 – 7.36 (m, 3H), 6.60 (s, 1H), 5.30 (s, 1H), 4.22 (td, J = 6.6, 1.4 Hz, 2H), 3.46 (sept, J =7.7 Hz, 1H), 2.57 (s, 3H), 1.73 – 1.64 (m, 2H), 1.43 (h, J = 7.4 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.7, 160.3, 148.7, 135.6, 129.3, 129.2,128.8, 123.1 (q, J = 281.6 Hz), 114.7, 110.8, 64.4, 50.7 (sept, J = 31.2 Hz),48.4, 30.9, 19.4, 14.0, 13.9. 19F NMR (376 MHz, CDCl3) δ -69.5 – -69.7 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C20H21F6O3S+455.1110, found 455.1098.

[0034] Compound 4 Example 5 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically pentyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester (compound 5), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, pentyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate (structural formula see [link]) is placed. Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol, 2.0 equiv) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0035] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 211 mg of pentyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 5, with a yield of 90%.

[0036] 1H NMR (400 MHz, CDCl3) δ 7.48 (dd, J = 8.0, 1.7 Hz, 2H), 7.45 – 7.34(m, 3H), 6.60 (s, 1H), 5.30 (s, 1H), 4.21 (td, J = 6.7, 1.6 Hz, 2H), 3.47(sept, J = 7.7 Hz, 1H), 2.57 (s, 3H), 1.70 (dq, J = 8.7, 6.7 Hz, 2H), 1.36(dtd, J = 10.2, 7.2, 5.8, 3.9 Hz, 4H), 0.91 (td, J = 5.8, 4.7, 2.4 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.7, 160.3, 148.7, 135.6, 129.3, 129.2,128.7, 123.1 (q, J = 281.7 Hz), 114.7, 110.8, 64.7, 50.7 (sept, J = 31.3 Hz),48.4, 28.5, 28.3, 22.5, 14.1, 14.0. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.7 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C21H23F6O3S+469.1267, found 469.1274.

[0037] Compound 5 Example 6 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically benzyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester (compound 6), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, benzyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate (CAS code 1927890-01-4; structural formula see [link to structural formula]) was prepared. Figure 1The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0038] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 225 mg of benzyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 6, with a yield of 92%.

[0039] 1 H NMR (400 MHz, CDCl3) δ 7.52 – 7.43 (m, 2H), 7.45 – 7.32 (m, 8H), 6.62 (s, 1H), 5.30 (s, 1H), 5.27 (d, J = 1.2 Hz, 2H), 3.46 (sept, J = 7.8 Hz,1H), 2.58 (s, 3H). 13 C NMR (151 MHz, CDCl3) δ 163.4, 160.7, 148.9, 136.1, 135.6, 129.3,129.2, 128.7, 128.7, 128.4, 128.3, 126.4 – 119.8 (m), 114.3, 110.7, 66.3, 50.7 (sept, J = 31.2 Hz), 48.4, 14.1. 19 F NMR (376 MHz, CDCl3) -69.4 – -69.7 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C23H19F6O3S+489.0954, found 489.0974.

[0040] Compound 6 Example 7 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically 2-(2-phenoxyethoxy)ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester (compound 7), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(2-phenoxyethoxy)ethyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate (CAS code 3070229-95-4; 2-(2-phenoxyethoxy)ethyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate; structural formula see Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O, 0.7 mmol of Pd(PPh3)2Cl2, 0.07 mmol of PPh3, and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0041] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 214 mg of 2-(2-phenoxyethoxy)ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 7, with a yield of 76%.

[0042] 1 H NMR (400 MHz, CDCl3) δ 7.50 – 7.44 (m, 2H), 7.43 – 7.35 (m, 3H), 7.30 – 7.22 (m, 2H), 6.97 – 6.87 (m, 3H), 6.60 (s, 1H), 5.28 (s, 1H), 4.40(td, J = 4.4, 2.4 Hz, 2H), 4.16 – 4.09 (m, 2H), 3.90 – 3.82 (m, 4H), 3.45(sept, J = 7.7 Hz, 1H), 2.56 (s, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.5, 160.7, 158.8, 148.8, 135.6, 129.6,129.3, 129.2, 128.7, 126.8 – 119.6 (m), 121.1, 114.7, 114.3, 110.8, 69.8,69.5, 67.5, 63.5, 50.7 (sept, J = 31.3 Hz), 48.4, 14.0. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.7 (m, 6F). HRMS-ESI m / z: [M+H]+ calcd for C26H25F6O3S+ 563.1321, found563.1319.

[0043] Compound 7 Example 8 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester (compound 8), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate (CAS code 3070230-01-9; (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (E)-2-acetyl-5-phenylpent-2-en-4-ynoate; structural formula see [see details]) Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol, CF3COCF3·3H2O (0.7 mmol), Pd(PPh3)2Cl2 (0.07 mmol), and PPh3 (1.8 mmol). 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0044] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 228 mg of (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 8, with a yield of 85%.

[0045] 1 H NMR (500 MHz, CDCl3) δ 7.48 (dt, J = 7.9, 1.6 Hz, 2H), 7.44 – 7.33(m, 3H), 6.59 (s, 1H), 5.31 (s, 1H), 4.84 (tt, J = 10.6, 4.9 Hz, 1H), 3.47(sept, J = 7.8 Hz, 1H), 2.72 – 2.37 (m, 3H), 2.14 – 2.00 (m, 1H), 1.90 (pd, J= 7.0, 2.7 Hz, 1H), 1.76 – 1.66 (m, 2H), 1.60 – 1.39 (m, 2H), 1.15 – 1.00 (m,2H), 0.91 (qd, J = 7.3, 6.8, 4.9 Hz, 7H), 0.78 (dd, J = 6.9, 2.9 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.3, 160.2, 135.7, 129.3, 129.2, 128.8,128.8, 123.1 (q, J = 279.9 Hz), 115.0, 110.8, 74.4, 50.7 (sept, J = 30.8 Hz),48.4, 47.4, 41.3, 34.4, 31.6, 26.6, 23.7, 22.2, 20.9, 16.6, 14.1. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.8 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C26H31F6O3S+ 537.1893, found537.1906.

[0046] Compound 8 Example 9 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-phenylfuran-3-carboxylic acid (compound 9), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-benzoyl-5-phenylpent-2-en-4-ynoate (CAS code 2055755-40-1; structural formula see [link to relevant documentation]) was prepared. Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of NiBr2·glyme (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0047] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 171 mg of ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-phenylfuran-3-carboxylic acid as shown in Formula 9, with a yield of 70%.

[0048] 1 H NMR (400 MHz, CDCl3) δ 7.98 – 7.91 (m, 2H), 7.61 – 7.51 (m, 2H), 7.48 – 7.37 (m, 6H), 6.82 (s, 1H), 5.41 (s, 1H), 4.29 (q, J = 7.1 Hz, 2H), 3.52 (sept, J = 7.6 Hz, 1H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 163.2, 158.4, 149.5, 135.5, 129.9, 129.4,129.3, 128.8, 128.6, 128.3, 123.1 (q, J = 280.2 Hz), 114.7, 112.9, 60.9, 50.7 (sept, J = 31.4 Hz), 48.4, 14.3. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.8 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C23H19F6O3S+ 489.0954, found489.0962.

[0049] Compound 9 Example 10 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 2-(4-fluorophenyl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid (compound 10), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-(4-fluorobenzoyl)-5-phenylpent-2-en-4-ynoate (CAS code 2055754-84-0; ethyl (E)-2-(4-fluorobenzoyl)-5-phenylpent-2-en-4-ynoate; structural formula see Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0050] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 127 mg of ethyl 2-(4-fluorophenyl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid as shown in Formula 10, with a yield of 50%.

[0051] 1 H NMR (400 MHz, CDCl3) δ 8.02 – 7.94 (m, 2H), 7.56 – 7.50 (m, 2H), 7.46 – 7.38 (m, 3H), 7.16 – 7.08 (m, 2H), 6.80 (s, 1H), 5.40 (s, 1H), 4.29(q, J = 7.1 Hz, 2H), 3.49 (sept, J = 7.6 Hz, 1H), 1.33 (t, J = 7.1 Hz, 3H). 13 C NMR (151 MHz, CDCl3) δ 163.6 (d, J = 250.9 Hz), 163.1, 157.5,149.5, 135.4, 130.7 (d, J = 8.5 Hz), 129.4, 129.4, 128.8, 125.5 (d, J = 3.4Hz), 126.2 – 119.8 (m), 115.5, 114.5, 112.9, 61.0, 50.7 (sept, J = 30.6 Hz), 48.4, 14.4. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.6 (m, 6F), -113.3 – -113.4 (m,1F). HRMS-ESI m / z : [M+H] + calcd for C23H18F7O3S+ 507.0859, found507.0866.

[0052] Compound 10 Example 11 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically 2-([1,1'-biphenyl]-4-yl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid ethyl ester (compound 11), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-benzoyl-5-phenyl-2-penten-4-ynoate (CAS code 3070229-78-3; ethyl (E)-2-([1,1'-biphenyl]-4-carbonyl)-5-phenylpent-2-en-4-ynoate; structural formula see Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3 (1.8 mmol). 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0053] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 203 mg of ethyl 2-([1,1'-biphenyl]-4-yl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid as shown in Formula 11, with a yield of 72%.

[0054] 1 H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 8.3 Hz, 2H), 7.67 (dd, J =16.5, 7.8 Hz, 4H), 7.57 (dd, J = 7.4, 1.8 Hz, 2H), 7.52 – 7.35 (m, 6H), 6.85(s, 1H), 5.44 (s, 1H), 4.33 (q, J = 7.1 Hz, 2H), 3.54 (hept, J = 7.7 Hz, 1H), 1.36 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 163.2, 158.2, 149.5, 142.6, 140.5, 135.5,129.4, 129.3, 129.0, 129.0, 128.8, 128.2, 127.9, 127.2, 127.0, 123.1 (q, J =282.8 Hz), 114.8, 113.0, 60.9, 50.8 (p, J = 31.2 Hz), 48.5, 14.4. 19 F NMR (565 MHz, CDCl3) δ -69.3 – -69.5 (m, 6F). HRMS-ESI m / z : [M+H] + calcd for C29H23F6O3S+ 565.1267, found565.1256.

[0055] Compound 11 Example 12 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(p-tolyl)furan-3-carboxylic acid (compound 12), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-(4-methylbenzoyl)-5-phenylpent-2-en-4-ynoate (CAS code 3070229-74-9; ethyl (E)-2-(4-methylbenzoyl)-5-phenylpent-2-en-4-ynoate; structural formula see Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0056] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 156 mg of ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(p-tolyl)furan-3-carboxylic acid, as shown in Formula 12, with a yield of 62%.

[0057] 1 H NMR (600 MHz, CDCl3) δ 7.83 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 7.5Hz, 2H), 7.41 – 7.31 (m, 3H), 7.22 (d, J = 7.8 Hz, 2H), 6.77 (s, 1H), 5.37(s, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.50 (sept, J = 7.6 Hz, 1H), 2.36 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.2, 158.8, 149.1, 140.2, 135.5, 129.4,129.3, 129.0, 128.8, 128.5, 126.5, 123.1 (q, J = 281.6 Hz), 114.1, 112.9,60.8, 50.8 (sept, J = 31.2 Hz), 48.5, 21.6, 14.3. 19 F NMR (565 MHz, CDCl3) δ -69.3 (q, J = 9.3 Hz, 3F), -69.5 (q, J =9.3 Hz, 3F). HRMS-ESI m / z : [M+H]+ calcd for C24H21F6O3S+ 503.1110, found503.1109.

[0058] Compound 12 Example 13 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 2-(4-butylphenyl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid (compound 13), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-(4-butylbenzoyl)-5-phenylpent-2-en-4-ynoate (CAS code 3070229-76-1; ethyl (E)-2-(4-butylbenzoyl)-5-phenylpent-2-en-4-ynoate; structural formula see Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0059] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 171 mg of ethyl 2-(4-butylphenyl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid as shown in Formula 13, with a yield of 63%.

[0060] 1 H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 8.2 Hz, 2H), 7.57 – 7.53 (m,2H), 7.46 – 7.36 (m, 3H), 7.27 (d, J = 7.9 Hz, 2H), 6.81 (s, 1H), 5.41 (s,1H), 4.30 (q, J = 7.1 Hz, 2H), 3.53 (sept, J = 7.6 Hz, 1H), 2.67 (t, J = 7.7Hz, 2H), 1.69 – 1.59 (m, 2H), 1.37 (dt, J = 20.7, 7.3 Hz, 5H), 0.95 (t, J =7.3 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.2, 158.8, 149.1, 145.1, 135.5, 129.4,129.3, 128.8, 128.5, 128.4, 126.7, 123.1 (q, J = 280.2 Hz), 114.1, 112.9,60.8, 50.8 (sept, J = 31.3 Hz), 48.5, 35.7, 33.5, 22.5, 14.4, 14.1. 19 F NMR (376 MHz, CDCl3) δ -69.4 (q, J = 8.2 Hz, 3F), -69.5 (q, J =8.4 Hz, 3F). HRMS-ESI m / z : [M+H]+ calcd for C27H27F6O3S+ 545.1580, found545.1573.

[0061] Compound 13 Example 14 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(m-tolyl)furan-3-carboxylic acid (compound 14), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-(3-methylbenzoyl)-5-phenylpent-2-en-4-ynoate (CAS code 3070229-81-8; structural formula see [link to structural formula]) was placed. Figure 1 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O, 0.7 mmol of Pd(PPh3)2Cl2, 0.07 mmol of PPh3, and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0062] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrated solution was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 173 mg of ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(m-tolyl)furan-3-carboxylic acid, as shown in Formula 14, with a yield of 69%.

[0063] 1 H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 8.2 Hz, 2H), 7.57 – 7.53 (m,2H), 7.46 – 7.36 (m, 3H), 7.27 (d, J = 7.9 Hz, 2H), 6.81 (s, 1H), 5.41 (s,1H), 4.30 (q, J = 7.1 Hz, 2H), 3.53 (sept, J = 7.6 Hz, 1H), 2.67 (t, J = 7.7Hz, 2H), 1.69 – 1.59 (m, 2H), 1.37 (dt, J = 20.7, 7.3 Hz, 5H), 0.95 (t, J =7.3 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.2, 158.8, 149.1, 145.1, 135.5, 129.4,129.3, 128.8, 128.5, 128.4, 126.7, 123.1 (q, J = 280.2 Hz), 114.1, 112.9,60.8, 50.8 (sept, J = 31.3 Hz), 48.5, 35.7, 33.5, 22.5, 14.4, 14.1. 19 F NMR (376 MHz, CDCl3) δ -69.4 (q, J = 8.2 Hz, 3F), -69.5 (q, J =8.4 Hz, 3F). – 1 HRMS-ESI m / z : [M+H]+ calcd for C27H27F6O3S+ 545.1580, found545.1573.

[0064] Compound 14 Example 15 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(o-tolyl)furan-3-carboxylic acid (compound 15), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-(2-methylbenzoyl)-5-phenylpent-2-en-4-ynoate (CAS code 2055754-86-2; ethyl (E)-2-(2-methylbenzoyl)-5-phenylpent-2-en-4-ynoate; structural formula see Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O, 0.7 mmol of Pd(PPh3)2Cl2, 0.07 mmol of PPh3, and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0065] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 230 mg of ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(o-tolyl)furan-3-carboxylic acid as shown in Formula 15, with a yield >99%.

[0066] 1 H NMR (400 MHz, CDCl3) δ 7.59 – 7.53 (m, 2H), 7.48 – 7.35 (m, 5H), 7.33 – 7.26 (m, 2H), 6.82 (s, 1H), 5.41 (s, 1H), 4.20 (qd, J = 7.1, 0.9 Hz, 2H), 3.55 (sept, J = 7.7 Hz, 1H), 2.25 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 162.9, 159.5, 150.1, 138.0, 135.5, 130.9,130.3, 130.0, 129.4, 129.4, 129.3, 128.8, 125.3, 123.1 (q, J = 280.4 Hz), 116.2, 111.3, 60.6, 50.7 (sept, J = 31.6 Hz), 48.5, 20.1, 14.1. 19 F NMR (376 MHz, CDCl3) δ -69.3 – -69.7 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C24H21F6O3S+ 503.1110, found503.1101.

[0067] Compound 15 Example 16 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(naphth-2-yl)furan-3-carboxylate (compound 16), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-(2-naphthoyl)-5-phenylpent-2-en-4-ynoate (CAS code 3070229-93-2; ethyl (E)-2-(2-naphthoyl)-5-phenylpent-2-en-4-ynoate; structural formula see Figure 2 The structural formula 16 in the text is as follows: 0.5 mmol), CF3COCF3 .3H2O (0.7 mmol), Pd(PPh3)2Cl2 (0.07 mmol), and PPh3 (1.8 mmol) are added to a dry sealed tube equipped with a magnetic stir bar, 5 mL of anhydrous CHCl2CH2Cl is added, the tube is capped and stirred at room temperature for 10 minutes; 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0068] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 164 mg of ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(naphth-2-yl)furan-3-carboxylic acid, as shown in Formula 16, with a yield of 61%.

[0069] 1 H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.01 (dd, J = 8.7, 1.7 Hz,1H), 7.96 – 7.84 (m, 3H), 7.59 – 7.51 (m, 4H), 7.48 – 7.39 (m, 3H), 6.87 (s,1H), 5.46 (s, 1H), 4.33 (q, J = 7.1 Hz, 2H), 3.56 (sept, J = 7.7 Hz, 1H), 1.34 (t, J = 7.1 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 163.2, 158.4, 149.7, 135.5, 133.8, 132.9,129.4, 129.3, 129.0, 128.8, 128.8, 127.9, 127.8, 127.3, 126.7, 126.6, 125.4,126.5 – 119.3 (m), 115.0, 113.1, 61.0, 50.8 (sept, J = 31.0 Hz), 48.5, 14.4. 19 F NMR (376 MHz, CDCl3) δ -69.4 (q, J = 8.1 Hz, 3F), -69.5 (q, J =8.3 Hz, 3F). HRMS-ESI m / z : [M+H]+ calcd for C27H21F6O3S+ 539.1110, found539.1117.

[0070] Compound 16 Example 17 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(thiophen-2-yl)furan-3-carboxylate (compound 17), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-5-phenyl-2-(thiophene-2-carbonyl)pent-2-en-4-ynoate (CAS code 3044060-58-1; ethyl (E)-5-phenyl-2-(thiophene-2-carbonyl)pent-2-en-4-ynoate; structural formula see Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0071] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 111 mg of ethyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-(thiophene-2-yl)furan-3-carboxylic acid as shown in Formula 17, with a yield of 45%.

[0072] 1 H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 3.8 Hz, 1H), 7.53 (d, J = 6.9Hz, 2H), 7.48 – 7.38 (m, 4H), 7.12 (dd, J = 5.0, 3.8 Hz, 1H), 6.76 (s, 1H), 5.39 (s, 1H), 4.39 – 4.27 (m, 2H), 3.55 (sept, J = 8.4 Hz, 1H), 1.38 (t, J =7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 163.0, 153.8, 148.9, 135.3, 131.0, 129.5,129.4, 129.3, 128.8, 128.8, 127.6, 123.0 (q, J = 293.3, 285.5 Hz), 112.9,112.5, 60.9, 50.8 (sept, J = 31.3 Hz), 48.3, 14.5. 19 F NMR (376 MHz, CDCl3) δ -69.4 (q, J = 8.4 Hz, 3F), -69.5 (q, J =8.5 Hz, 3F). HRMS-ESI m / z: [M+H]+ calcd for C21H17F6O3S2 + 495.0518, found495.0513.

[0073] Compound 17 Example 18 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically benzyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-phenylfuran-3-carboxylic acid ester (compound 18), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, benzyl (E)-2-benzoyl-5-phenylpent-2-en-4-ynoate (CAS code 3070229-72-7; structural formula see [link to structural formula]) was prepared. Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0074] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 193 mg of benzyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-phenylfuran-3-carboxylic acid ester as shown in Formula 18, with a yield of 70%.

[0075] 1 H NMR (400 MHz, CDCl3) δ 7.99 – 7.86 (m, 2H), 7.58 – 7.48 (m, 2H), 7.41 (dtd, J = 8.3, 4.2, 2.4 Hz, 6H), 7.39 – 7.34 (m, 5H), 6.84 (s, 1H), 5.39(s, 1H), 5.28 (d, J = 3.7 Hz, 2H), 3.50 (sept, J = 7.7 Hz, 1H). 13 C NMR (126 MHz, CDCl3) δ 162.9, 158.8, 149.6, 135.8, 135.4, 130.0,129.4, 129.3, 129.2, 128.8, 128.7, 128.6, 128.5, 128.5, 128.3, 123.1 (q, J =280.3 Hz), 114.4, 112.8, 66.6, 50.8 (sept, J = 31.2 Hz), 48.4. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.7 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C28H21F6O3S+ 551.1110, found551.1090.

[0076] Compound 18 Example 19 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methyl-3-p-toluenesulfonylfuran (compound 19), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, (E)-6-phenyl-3-p-tosylhex-3-en-5-yn-2-one (CAS code 2379761-36-9; (E)-6-phenyl-3-tosylhex-3-en-5-yn-2-one; structural formula see [link to structural formula]). Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0077] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using petroleum ether / ethyl acetate at a ratio of 40:1. The column effluent was concentrated by rotary evaporation and dried to obtain 255 mg of 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methyl-3-p-toluenesulfonylfuran as shown in Formula 19, with a yield >99%.

[0078] 1 H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.4 Hz, 2H), 7.44 – 7.38 (m,5H), 7.33 – 7.29 (m, 2H), 6.50 (s, 1H), 5.24 (s, 1H), 3.38 (sept, J = 7.7 Hz,1H), 2.56 (s, 3H), 2.41 (s, 3H). 13 C NMR (151 MHz, CDCl3) δ 157.3, 150.1, 144.5, 139.3, 134.9, 130.1,129.5, 129.4, 128.7, 127.1, 124.3, 127.0 – 121.8 (m), 109.4, 50.6 (sept, J =31.3 Hz), 48.2, 21.7, 13.1. 19F NMR (376 MHz, CDCl3) δ -69.5 (p, J = 9.2 Hz, 3F), -69.7 (p, J =9.4 Hz, 3F). HRMS-ESI m / z: [M+H]+ calcd for C22H19F6O3S2 + 509.0674, found509.0657.

[0079] Compound 19 Example 20 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically 1-(5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-yl)ethane-1-one (compound 20), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 3-(3-phenylprop-2-yn-1-ylidene)pentane-2,4-dione (CAS code 67082-95-5; 3-(3-phenylprop-2-yn-1-ylidene)pentane-2,4-dione; structural formula see [link to structural formula]). Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: CF3COCF3·3H2O (0.5 mmol), NiBr2·glyme (0.07 mmol), and PPh3 (1.8 mmol). 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0080] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 134 mg of 1-(5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-yl)ethane-1-one as shown in Formula 20, with a yield of 73%.

[0081] 1H NMR (600 MHz, CDCl3) δ 7.48 (d, J = 6.8 Hz, 2H), 7.45 – 7.34 (m,3H), 6.57 (s, 1H), 5.32 (s, 1H), 3.48 (sept, J = 7.4 Hz, 1H), 2.58 (s, 3H),2.38 (s, 3H). 13 C NMR (151 MHz, CDCl3) δ 193.7, 159.5, 148.9, 135.6, 129.4, 129.3,128.7, 126.1 – 120.1 (m), 122.3, 110.3, 50.7 (sept, J = 31.2 Hz), 48.4, 29.2,14.6. 19 F NMR (376 MHz, CDCl3) δ -69.6 (d, J = 7.8 Hz, 6F). HRMS-ESI m / z : [M+H]+ calcd for C17H15F6O2S+ 397.0691, found397.0692.

[0082] Compound 20 Example 21 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 21), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 1,3-diphenyl-2-(3-phenylprop-2-yn-1-ylidene)propane-1,3-dione (CAS code 1622061-90-8; 1,3-diphenyl-2-(3-phenylprop-2-yn-1-ylidene)propane-1,3-dione; structural formula see [see details]) Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of NiBr2·glyme (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0083] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using petroleum ether / ethyl acetate at a ratio of 40:1. The column effluent was concentrated by rotary evaporation and dried to obtain 261 mg of (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone as shown in Formula 21, with a yield >99%.

[0084] 1 H NMR (400 MHz, CDCl3) δ 7.83 – 7.78 (m, 2H), 7.68 – 7.63 (m, 2H), 7.60 – 7.49 (m, 3H), 7.48 – 7.36 (m, 5H), 7.34 – 7.28 (m, 3H), 6.68 (s, 1H),5.47 (s, 1H), 3.57 (sept, J = 7.7 Hz, 1H). 13 C NMR (126 MHz, CDCl3) δ 191.3, 156.9, 149.8, 137.8, 135.4, 133.2,129.8, 129.6, 129.5, 129.4, 129.3, 128.9, 128.6, 128.5, 127.7, 127.1 – 118.9(m), 121.6, 113.4, 50.8 (sept, J = 31.3 Hz), 48.6. 19 F NMR (376 MHz, CDCl3) δ -69.5 (d, J = 7.2 Hz, 6F). HRMS-ESI m / z : [M+H]+ calcd for C27H19F6O2S+ 521.1004, found521.1015.

[0085] Compound 21 Example 22 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(p-tolyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 22), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 1,3-diphenyl-2-(3-(p-tolyl)prop-2-yn-1-ylidene)propane-1,3-dione (CAS code 2322245-18-9; 1,3-diphenyl-2-(3-(p-tolyl)prop-2-yn-1-ylidene)propane-1,3-dione; structural formula see [link to structural formula]). Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O, 0.7 mmol of NiBr2·glyme, 0.07 mmol of PPh3, and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0086] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 262 mg of (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(p-tolyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone, as shown in Formula 22, with a yield of 98%.

[0087] 1 H NMR (400 MHz, CDCl3) δ 7.84 – 7.76 (m, 2H), 7.64 (ddd, J = 6.6,2.7, 1.4 Hz, 2H), 7.56 – 7.47 (m, 1H), 7.48 – 7.42 (m, 2H), 7.38 (t, J = 7.7Hz, 2H), 7.35 – 7.27 (m, 3H), 7.24 (d, J = 7.9 Hz, 2H), 6.66 (s, 1H), 5.44(s, 1H), 3.55 (sept, J = 7.7 Hz, 1H), 2.38 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.4, 156.8, 150.1, 139.4, 137.8, 133.2,132.3, 130.1, 129.8, 129.5, 129.3, 128.8, 128.5, 128.5, 127.7, 123.1 (q, J =281.7 Hz), 121.6, 113.3, 50.8 (sept, J = 31.3 Hz), 48.3, 21.3. 19 F NMR (376 MHz, CDCl3) δ -69.2 – -69.6 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C28H21F6O2S+ 535.1161, found535.1170.

[0088] Compound 22 Example 23 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-((4-ethylphenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 23), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-(4-ethylphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (CAS code 2891954-26-8; 2-(3-(4-ethylphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see [see details]) Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of NiBr2·glyme, and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0089] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 277 mg of (5-((4-ethylphenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone as shown in Formula 23, with a yield >99%.

[0090] 1 H NMR (400 MHz, CDCl3) δ 7.83 – 7.78 (m, 2H), 7.68 – 7.62 (m, 2H), 7.55 – 7.46 (m, 3H), 7.39 (t, J = 7.8 Hz, 2H), 7.34 – 7.23 (m, 5H), 6.68 (s,1H), 5.45 (s, 1H), 3.57 (sept, J = 7.7 Hz, 1H), 2.69 (q, J = 7.6 Hz, 2H), 1.26 (t, J = 7.6 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 191.4, 156.8, 150.1, 145.6, 137.8, 133.2,132.5, 129.8, 129.5, 129.3, 128.9, 128.8, 128.5, 128.5, 127.7, 126.8 – 119.6(m), 121.6, 113.3, 50.8 (sept, J = 31.3 Hz), 48.3, 28.7, 15.4. 19 F NMR (376 MHz, CDCl3) δ -69.4 (d, J = 7.9 Hz, 6F). HRMS-ESI m / z : [M+H]+ calcd for C29H23F6O2S+ 549.1317, found549.1321.

[0091] Compound 23 Example 24 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(4-isopropylphenyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 24), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-(4-isopropylphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (2-(3-(4-isopropylphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see [link to structural formula]). Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O, 0.7 mmol of NiBr2·glyme, 0.07 mmol of PPh3, and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0092] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 219 mg of (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(4-isopropylphenyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone, as shown in Formula 24, with a yield of 78%.

[0093] 1 H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.5 Hz, 2H), 7.64 (dd, J =6.8, 3.0 Hz, 2H), 7.55 – 7.43 (m, 3H), 7.37 (t, J = 7.7 Hz, 2H), 7.32 – 7.24(m, 5H), 6.66 (s, 1H), 5.43 (s, 1H), 3.57 (sept, J = 7.6 Hz, 1H), 2.93 (sept,J = 7.1 Hz, 1H), 1.26 (d, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 191.4, 156.8, 150.2, 150.1, 137.8, 133.2,132.6, 129.8, 129.5, 129.3, 128.8, 128.5, 128.5, 127.7, 127.5, 126.8 – 119.4(m), 121.6, 113.3, 50.8 (sept, J = 31.1 Hz), 48.3, 34.0, 24.0. 19 F NMR (376 MHz, CDCl3) δ -69.3 – -69.6 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C30H25F6O2S+ 563.1474, found563.1478.

[0094] Compound 24 Example 25 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-((4-butylphenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 25), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-(4-butylphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (2-(3-(4-butylphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see [link to structural formula]). Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: CF3COCF3·3H2O (0.5 mmol), NiBr2·glyme (0.07 mmol), and PPh3 (1.8 mmol). 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0095] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 248 mg of (5-((4-butylphenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone, as shown in Formula 25, with a yield of 86%.

[0096] 1 H NMR (400 MHz, CDCl3) δ 7.84 – 7.77 (m, 2H), 7.68 – 7.62 (m, 2H), 7.56 – 7.43 (m, 3H), 7.42 – 7.34 (m, 2H), 7.34 – 7.29 (m, 3H), 7.26 – 7.22(m, 2H), 6.68 (s, 1H), 5.44 (s, 1H), 3.56 (sept, J = 7.7 Hz, 1H), 2.62 (d, J= 7.7 Hz, 2H), 1.66 – 1.56 (m, 2H), 1.36 (h, J = 7.4 Hz, 2H), 0.93 (t, J =7.3 Hz, 3H). 13 C NMR (126 MHz, CDCl3) δ 191.4, 156.8, 150.1, 144.4, 137.8, 133.2,132.5, 129.8, 129.5, 129.4, 129.3, 128.7, 128.5, 128.5, 127.7, 126.9 – 119.4(m), 121.6, 113.3, 50.8 (sept, J = 30.9 Hz), 48.4, 35.5, 33.5, 22.5, 14.0. 19 F NMR (376 MHz, CDCl3) δ -69.5 (d, J = 7.8 Hz, 6F). HRMS-ESI m / z : [M+H]+ calcd for C31H27F6O2S+ 577.1630, found577.1631.

[0097] Compound 25 Example 26 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-((4-(tert-butyl)phenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 26), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-(4-butylphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (2-(3-(4-(tert-butyl)phenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see [link to structural formula]). Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O, 0.7 mmol of NiBr2·glyme, 0.07 mmol of PPh3, and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0098] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 245 mg of (5-((4-(tert-butyl)phenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone as shown in Formula 26, with a yield of 86%.

[0099] 1 H NMR (400 MHz, CDCl3) δ 7.84 – 7.75 (m, 2H), 7.68 – 7.63 (m, 2H), 7.55 – 7.43 (m, 5H), 7.38 (t, J = 7.7 Hz, 2H), 7.34 – 7.29 (m, 3H), 6.69 (s,1H), 5.45 (s, 1H), 3.60 (sept, J = 7.6 Hz, 1H), 1.34 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 191.4, 156.8, 152.5, 150.1, 137.8, 133.2,132.3, 129.8, 129.5, 129.3, 128.5, 128.5, 128.5, 127.7, 126.4, 126.5 – 118.8(m), 121.6, 113.3, 50.9 (sept, J = 31.2 Hz), 48.3, 34.9, 31.4. 19 F NMR (376 MHz, CDCl3) δ -69.4 (q, J = 8.1 Hz, 3F), -69.5 (q, J =8.3 Hz, 3F). HRMS-ESI m / z : [M+H]+ calcd for C31H27F6O2S+ 577.1630, found577.1636.

[0100] Compound 26 Example 27 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-([1,1'-biphenyl]-4-yl((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 27), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-([1,1'-biphenyl]-4-yl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (2-(3-([1,1'-biphenyl]-4-yl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see Figure 2 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of NiBr2·glyme (1.8 mmol), 5 mL of anhydrous CHCl2CH2Cl, and the tube was capped and stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0101] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 244 mg of (5-([1,1'-biphenyl]-4-yl((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone, as shown in Formula 27, with a yield of 82%.

[0102] 1 H NMR (400 MHz, CDCl3) δ 7.84 – 7.78 (m, 2H), 7.68 – 7.58 (m, 7H), 7.49 (dt, J = 23.0, 7.6 Hz, 4H), 7.38 (t, J = 7.8 Hz, 3H), 7.32 (p, J = 3.4,2.8 Hz, 3H), 6.72 (s, 1H), 5.51 (s, 1H), 3.61 (sept, J = 7.6 Hz, 1H). 13 C NMR (126 MHz, CDCl3) δ 191.3, 156.9, 149.8, 142.3, 140.2, 137.8,134.3, 133.2, 129.8, 129.6, 129.3, 129.3, 129.0, 128.6, 128.6, 128.1, 127.9,127.8, 127.3, 126.6 – 119.5 (m), 121.6, 113.5, 50.9 (sept, J = 31.1 Hz),48.3. 19 F NMR (376 MHz, CDCl3) δ -69.3 – -69.6 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C33H23F6O2S+ 597.1317, found597.1323.

[0103] Compound 27 Example 28 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(4-methoxyphenyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 28), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-(4-methoxyphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (CAS code 2088642-10-6; 2-(3-(4-methoxyphenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see [see details]) Figure 3 The following components were added to a dry sealed tube equipped with a magnetic stir bar: CF3COCF3·3H2O (0.7 mmol), NiBr2·glyme (0.07 mmol), and PPh3 (1.8 mmol). 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0104] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 217 mg of (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(4-methoxyphenyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone, as shown in Formula 28, with a yield of 79%.

[0105] 1 H NMR (500 MHz, CDCl3) δ 7.79 (dd, J = 8.1, 1.3 Hz, 2H), 7.64 (dd, J= 6.7, 2.9 Hz, 2H), 7.54 – 7.43 (m, 3H), 7.37 (t, J = 7.7 Hz, 2H), 7.30 (p, J = 3.5, 3.0 Hz, 3H), 6.95 (d, J = 8.7 Hz, 2H), 6.64 (s, 1H), 5.43 (s, 1H), 3.83 (s, 3H), 3.54 (sept, J = 7.8 Hz, 1H). 13 C NMR (126 MHz, CDCl3) δ 191.4, 160.3, 156.8, 150.2, 137.8, 133.2,130.2, 129.8, 129.5, 129.3, 128.5, 128.5, 127.7, 127.1, 126.7 – 119.6 (m),121.6, 114.8, 113.2, 55.5, 50.8 (sept, J = 31.4 Hz), 48.0. 19 F NMR (376 MHz, CDCl3) δ -69.3 – -69.6 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C28H21F6O3S+ 551.1110, found551.1114.

[0106] Compound 28 Example 29 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-((4-((benzyloxy)methyl)phenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 29), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-(4-(benzyloxy)phenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (2-(3-(4-((benzyloxy)methyl)phenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see [link to structural formula]). Figure 3 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of NiBr2·glyme (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0107] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 240 mg of (5-((4-((benzyloxy)methyl)phenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone of formula 29, with a yield of 75%.

[0108] 1 H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 7.4 Hz, 2H), 7.64 (dd, J =6.8, 3.0 Hz, 2H), 7.58 – 7.49 (m, 3H), 7.44 (d, J = 7.9 Hz, 2H), 7.41 – 7.35(m, 6H), 7.31 (p, J = 3.9, 3.2 Hz, 4H), 6.67 (s, 1H), 5.47 (s, 1H), 4.60 (s,2H), 4.58 (s, 2H), 3.56 (sept, J = 7.6 Hz, 1H). 13 C NMR (126 MHz, CDCl3) δ 191.3, 156.9, 149.8, 139.8, 138.1, 137.8,134.7, 133.2, 129.8, 129.6, 129.2, 128.9, 128.6, 128.6, 128.5, 127.9, 127.9,127.7, 128.4 – 121.6 (m), 121.6, 113.4, 72.7, 71.6, 50.7 (sept, J = 31.6 Hz),48.3. 19 F NMR (376 MHz, CDCl3) δ -69.4 (d, J = 7.7 Hz, 6F). HRMS-ESI m / z :[M+H]+ calcd for C35H27F6O3S+ 641.1580, found 641.1584.

[0109] Compound 29 Example 30 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(m-tolyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 30), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 1,3-diphenyl-2-(3-(m-tolyl)prop-2-yn-1-ylidene)propane-1,3-dione (CAS code 2088642-11-7; 1,3-diphenyl-2-(3-(m-tolyl)prop-2-yn-1-ylidene)propane-1,3-dione; structural formula see [see details]) Figure 3 The structural formula 30 in the text is as follows: 0.5 mmol), CF3COCF3·3H2O (0.7 mmol), NiBr2·glyme (0.07 mmol), and PPh3 (1.8 mmol) are added to a dry sealed tube equipped with a magnetic stir bar, 5 mL of anhydrous CHCl2CH2Cl is added, the tube is capped and stirred at room temperature for 10 minutes; 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0110] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain (5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(m-tolyl)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (mg, yield >99%), as shown in Formula 30.

[0111] 1 H NMR (400 MHz, CDCl3) δ 7.81 – 7.76 (m, 2H), 7.66 – 7.61 (m, 2H), 7.55 – 7.48 (m, 1H), 7.42 – 7.27 (m, 8H), 7.20 (d, J = 7.4 Hz, 1H), 6.67 (s,1H), 5.42 (s, 1H), 3.56 (sept, J = 7.6 Hz, 1H), 2.39 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.3, 156.7, 150.1, 139.3, 137.9, 135.4,133.2, 130.1, 129.8, 129.5, 129.5, 129.4, 129.3, 128.6, 128.5, 127.8, 125.9,128.8 – 121.8 (m), 121.7, 113.3, 50.9 (sept, J = 31.2 Hz), 48.6, 21.5. 19 F NMR (376 MHz, CDCl3) δ -69.4 – -69.6 (m, 6F). HRMS-ESI m / z : [M+H]+ calcd for C28H21F6O2S+ 535.1161, found535.1171.

[0112] Compound 30 Example 31 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 2-(3-chlorophenyl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid (compound 31), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-(3-chlorobenzoyl)-5-phenylpent-2-en-4-ynoate (structural formula see [link to glove box]) is placed. Figure 3 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0113] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 256 mg of ethyl 2-(3-chlorophenyl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid as shown in Formula 31, with a yield of 98%.

[0114] 1 H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 2.1 Hz, 1H), 7.87 (dt, J =5.8, 1.9 Hz, 1H), 7.53 (dd, J = 8.0, 1.6 Hz, 2H), 7.48 – 7.36 (m, 5H), 6.84(s, 1H), 5.42 (s, 1H), 4.31 (q, J = 7.1 Hz, 2H), 3.51 (sept, J = 7.7 Hz, 1H), 1.35 (t, J = 7.2 Hz, 3H). 13 C NMR (151 MHz, CDCl3) δ 162.9, 156.5, 150.1, 135.3, 134.3, 130.9,129.8, 129.6, 129.5, 129.4, 128.8, 128.5, 126.6, 126.1 – 119.8 (m), 115.6,113.0, 61.1, 50.7 (sept, J = 31.4 Hz), 48.4, 14.3. 19 F NMR (376 MHz, CDCl3) δ -69.5 (d, J = 7.2 Hz, 6F). HRMS-ESI m / z : [M+H]+ calcd for C23H18ClF6O3S+ 523.0564, found523.0570.

[0115] Compound 31 Example 32 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically ethyl 2-(3-bromophenyl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid (compound 32), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, ethyl (E)-2-(3-bromobenzoyl)-5-phenylpent-2-en-4-ynoate (structural formula see [link]) is placed. Figure 3 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of Pd(PPh3)2Cl2 (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0116] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 212 mg of ethyl 2-(3-bromophenyl)-5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)furan-3-carboxylic acid as shown in Formula 32, with a yield of 75%.

[0117] 1 H NMR (400 MHz, CDCl3) δ 8.14 (t, J = 1.8 Hz, 1H), 7.91 (dt, J =8.0, 1.3 Hz, 1H), 7.58 – 7.49 (m, 3H), 7.48 – 7.35 (m, 3H), 7.31 (t, J = 8.0Hz, 1H), 6.84 (s, 1H), 5.42 (s, 1H), 4.31 (q, J = 7.1 Hz, 2H), 3.51 (sept, J= 7.7 Hz, 1H), 1.35 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 162.8, 156.3, 150.2, 135.3, 132.7, 131.4,131.1, 129.8, 129.5, 129.4, 128.8, 127.1, 126.0 – 120.0 (m), 122.3, 115.7,113.0, 61.1, 50.7 (sept, J = 31.2 Hz), 48.4, 14.3. 19 F NMR (376 MHz, CDCl3) δ -69.4 (d, J = 7.6 Hz, 6F). HRMS-ESI m / z : [M+H]+ calcd for C23H18BrF6O3S+ 567.0059, found567.0063.

[0118] Compound 32 Example 33 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-((3-chlorophenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 33), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-(3-chlorophenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (CAS code 2878569-46-9; 2-(3-(3-chlorophenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see [see details]) Figure 3 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of NiBr2·glyme (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0119] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 244 mg of (5-((3-chlorophenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone as shown in Formula 33, with a yield of 88%.

[0120] 1 H NMR (400 MHz, CDCl3) δ 7.83 – 7.78 (m, 2H), 7.64 (dd, J = 6.7, 3.0Hz, 2H), 7.59 – 7.44 (m, 3H), 7.42 – 7.35 (m, 4H), 7.34 – 7.28 (m, 3H), 6.71(s, 1H), 5.42 (s, 1H), 3.60 (sept, J = 7.6 Hz, 1H). 13 C NMR (151 MHz, CDCl3) δ 191.2, 157.1, 149.0, 137.6, 137.5, 135.3,133.3, 130.7, 129.8, 129.7, 129.6, 129.1, 128.9, 128.6, 127.7, 126.9, 126.3 –119.8 (m), 121.6, 113.7, 50.9 (sept, J = 31.2 Hz), 48.0. 19 F NMR (376 MHz, CDCl3) δ -69.3 (p, J = 8.7, 3F), -69.5 (p, J = 9.1Hz, 3F). HRMS-ESI m / z : [M+H]+ calcd for C27H18ClF6O2S+ 555.0615, found555.0623.

[0121] Compound 33 Example 34 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically (5-((2-chlorophenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone (compound 34), is prepared by the following steps: 1) In a glove box filled with inert gas Ar, 2-(3-(2-chlorophenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione (CAS code 2878569-48-1; 2-(3-(2-chlorophenyl)prop-2-yn-1-ylidene)-1,3-diphenylpropane-1,3-dione; structural formula see [see details]) Figure 3 The following components were added to a dry sealed tube equipped with a magnetic stir bar: 0.5 mmol of CF3COCF3·3H2O (0.7 mmol), 0.07 mmol of NiBr2·glyme (0.07 mmol), and 1.8 mmol of PPh3. 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped, and the mixture was stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw SOCl2 (1.0 mmol) and inject it into the reactants obtained in step 1); then close the stopcock and stir at 110°C for 12 h.

[0122] 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 205 mg of (5-((2-chlorophenyl)((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)methyl)-2-phenylfuran-3-yl)(phenyl)methyl ketone, as shown in Formula 34, with a yield of 74%.

[0123] 1 H NMR (400 MHz, CDCl3) δ 7.82 (ddd, J = 13.2, 8.1, 1.7 Hz, 3H), 7.68– 7.62 (m, 2H), 7.55 – 7.49 (m, 1H), 7.46 (dd, J = 7.8, 1.6 Hz, 1H), 7.42 –7.35 (m, 3H), 7.35 – 7.28 (m, 4H), 6.71 (s, 1H), 6.08 (s, 1H), 3.68 (sept, J= 7.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 191.3, 157.1, 148.9, 137.7, 133.8, 133.4,133.2, 130.4, 130.3, 129.8, 129.6, 129.2, 128.6, 128.5, 128.0, 127.7, 123.0(q, J = 279.1 Hz), 121.6, 113.9, 51.0 (sept, J = 31.4 Hz), 44.4. 19 F NMR (376 MHz, CDCl3) δ -69.4 (q, J = 9.2 Hz, 3F), -69.6 (q, J =9.4 Hz, 3F). HRMS-ESI m / z : [M+H]+ calcd for C27H18ClF6O2S+ 555.0615, found555.0621.

[0124] Compound 34 Comparative Example 1 An antitumor active furan-substituted hexafluoroisopropyl sulfide, specifically a methyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester, is prepared by the following steps: 1) In a glove box filled with inert gas Ar, methyl (E)-2-acetyl-5-phenylpent-2-ene-4-acetylacetate (0.5 mmol), CF3COCF3·3H2O (0.7 mmol), Pd(PPh3)2Cl2 (0.07 mmol), and PPh3 (1.8 mmol) were added to a dry sealed tube equipped with a magnetic stir bar, 5 mL of anhydrous CHCl2CH2Cl was added, the tube was capped and stirred at room temperature for 10 minutes. 2) Open the stopcock, use a microsyringe to draw up Tf2O (1.0 mmol) and inject it into the reactant obtained in step 1); then close the stopcock and stir at 110°C for 12 h. 3) After the reaction was completed, the reaction solution was concentrated by rotary evaporation under reduced pressure. The concentrate was then separated by column chromatography using pure petroleum ether as the eluent. The column chromatography effluent was concentrated by rotary evaporation and dried to obtain 108 mg of methyl 5-(((1,1,1,3,3,3-hexafluoropropane-2-yl)thio)(phenyl)methyl)-2-methylfuran-3-carboxylic acid ester as shown in Formula 1, with a yield of <10%.

[0125]

[0126] Compound 35 The substrates of compounds 5, 24, 25, 26, 27, 29, 31, and 32 mentioned above do not have CAS codes. Their corresponding structural formulas in the attached figures are 5, 24, 25, 26, 27, 29, 31, and 32. The preparation methods include the following steps: 1) In a 50 mL round-bottom flask, dissolve 1,3-dione (5 mmol), AcOH (0.2 equiv), piperidine (0.1 equiv), anhydrous magnesium sulfate (1.0 equiv), and acetylene (1.2 equiv) in 20 mL of toluene, and heat at 40 °C. o Stir in a water bath for 4 hours. After confirming the reaction is complete by TLC spot monitoring, cool to room temperature.

[0127] 2) Add saturated brine and extract the aqueous phase using EA (2 × 30 mL). Combine the organic phases, dry with anhydrous Na₂SO₄, and filter. Concentrate the filtrate under reduced pressure to obtain the crude product. Perform silica gel column chromatography with petroleum ether and ethyl acetate in a specific ratio as eluents. Finally, the enynyl ketone substrate is obtained.

[0128] Further, the furan-substituted hexafluoroisopropyl sulfide obtained in the examples was used as an antitumor active agent for antitumor activity testing. The specific steps included the following: human cervical cancer cells HeLa, human breast cancer cells MDA-MB-231, and human breast cancer cells MCF-7 were cultured in DMEM complete medium. When they grew to the logarithmic growth phase, the cells were digested with trypsin, and the cell suspension was diluted to approximately 8 × 10⁻⁶ cells / mL. 4 Cells were seeded. Next, 100 μL of cell suspension was seeded into each well of a 96-well plate and cultured at 37°C and 5% CO2 for 24 h. After cell adhesion, drug treatment was performed. Compound solutions of different concentration gradients (from 100 to 0.78125 μM, decreasing in a gradient) were prepared using DMEM complete medium, with three replicates for each concentration and two blank control groups. The 96-well plates were then incubated for 48 h. After 48 h of culture, the culture medium was removed, the cells were washed with PBS buffer, and 10% CCK-8 solution (prepared using phenol red-free DMEM complete medium) was added under light-protected conditions and incubated for 1–2 h. Finally, the absorbance (OD value) of each well was measured at 450 nm using a microplate reader. The IC50 and other data for cell inhibition could be calculated based on the obtained OD values.

[0129] Using 5-FU as a positive control, antitumor activity data for several compounds were obtained, and the results are shown in Table 1.

[0130] Table 1. Antitumor activity data of embodiments of the present invention

[0131] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

[0132] The above embodiments are merely illustrative and do not constitute a limitation on the scope of protection of this invention. Guided by the technical concept of this invention, those skilled in the art can make reasonable adjustments and improvements to the process parameters, reagent types, or operating procedures without departing from the spirit and scope defined by the claims. Such modifications all fall within the protection scope of this invention.

Claims

1. A furan-substituted hexafluoroisopropyl sulfide with antitumor activity, characterized in that, Its structure is shown in Equation I: I In Formula I, R1 is one of carbonyl, alkoxyacyl, and benzyloxyacyl; R2 is one or more of alkyl, aryl, heteroaryl, halogen, and methyl; and R3 is one of hydrogen, alkyl, and halogen.

2. The antitumor active furan-substituted hexafluoroisopropyl sulfide according to claim 1, characterized in that, In R2, the alkyl group is a C1-C4 straight-chain alkyl group; the heteroaryl group is thiophene; and in R3, the alkyl group is a C1-C5 straight-chain alkyl group.

3. The antitumor active furan-substituted hexafluoroisopropyl sulfide according to claim 1, characterized in that, The specific structural formula of the antitumor active furan-substituted hexafluoroisopropyl sulfide includes the following: or .

4. The method for preparing the antitumor active furan-substituted hexafluoroisopropyl sulfide according to any one of claims 1 to 3, characterized in that, Includes the following steps: 1) Under a protective atmosphere and at room temperature, the enynyl ketone substrate, hexafluoroacetone, triphenylphosphine and catalyst were dissolved in the reaction solvent and the reaction was carried out with stirring at room temperature; 2) Inject thionyl chloride into the reactants obtained in step 1), and then heat and stir the reaction to obtain the target product, antitumor active furan-substituted hexafluoroisopropyl sulfide.

5. The preparation method according to claim 4, characterized in that, The enynyl ketone substrate is a conjugated enynyl ketone.

6. The preparation method according to claim 4, characterized in that, The catalyst is one or more of palladium-based catalysts, copper salt catalysts, iron-based catalysts, and nickel-based catalysts.

7. The preparation method according to claim 4, characterized in that, The reaction solvent is one or more of toluene, carbon tetrachloride, 1,2-dichloroethane, 1,1,2-trichloroethane, and 1,1,2,2-tetrachloroethane.

8. The preparation method according to claim 4, characterized in that, The room temperature stirring reaction time is 1-20 min; the heated stirring reaction is carried out under sealed conditions, and the reaction temperature is 105-115 °C. o C, the time is 10-12 hours.

9. The preparation method according to claim 4, characterized in that, The molar ratio of conjugated enynyl ketone, hexafluoroacetone hydrate, triphenylphosphine, thionyl chloride, and catalyst is 1:1.3-1.5:3.5-3.8:1.8-2.2:0.1-0.

15.

10. The use of the antitumor active furan-substituted hexafluoroisopropyl sulfide according to any one of claims 1 to 3 as an antitumor active agent.